This company listing is no longer active
23N Stock Overview
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nuvo Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.90 |
| 52 Week High | CA$1.10 |
| 52 Week Low | CA$0.34 |
| Beta | 0.78 |
| 1 Month Change | -0.55% |
| 3 Month Change | 109.30% |
| 1 Year Change | -3.23% |
| 3 Year Change | 97.37% |
| 5 Year Change | n/a |
| Change since IPO | -94.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 23N | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.6% | -3.4% | -1.1% |
| 1Y | -3.2% | -14.4% | 8.1% |
Return vs Industry: 23N exceeded the German Pharmaceuticals industry which returned -8.9% over the past year.
Return vs Market: 23N exceeded the German Market which returned -13.7% over the past year.
Price Volatility
| 23N volatility | |
|---|---|
| 23N Average Weekly Movement | 30.2% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 23N's share price has been volatile over the past 3 months.
Volatility Over Time: 23N's weekly volatility has increased from 23% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 101 | Jesse Ledger | www.miravohealthcare.com |
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations.
Nuvo Pharmaceuticals Inc. Fundamentals Summary
| 23N fundamental statistics | |
|---|---|
| Market cap | €10.56m |
| Earnings (TTM) | €10.42m |
| Revenue (TTM) | €49.72m |
1.0x
P/E Ratio0.2x
P/S RatioIs 23N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 23N income statement (TTM) | |
|---|---|
| Revenue | CA$72.42m |
| Cost of Revenue | CA$27.36m |
| Gross Profit | CA$45.06m |
| Other Expenses | CA$29.89m |
| Earnings | CA$15.17m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.33 |
| Gross Margin | 62.22% |
| Net Profit Margin | 20.95% |
| Debt/Equity Ratio | 1,149.7% |
How did 23N perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/17 13:06 |
| End of Day Share Price | 2023/03/16 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nuvo Pharmaceuticals Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Mark Knapp | Clarus Securities Inc. |
| null null | Eight Capital |